...
search icon
bnr-img

Burning Rock Biotech Ltd, Common Stock

BNR

NMQ

$3.7202

+$0.16

(4.5%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$43.39M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.74
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.18 L
$7.9 H
$3.7202

About Burning Rock Biotech Ltd, Common Stock

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS) based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various cancer types, including pan-cancer, lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, and ovarian cancer. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples, and OncoCompass, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore, which assesses microsatellite loci related to MSI status and detects mutations in genes associated with gastrointestinal cancers. It also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of the key products. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBNRSectorS&P500
1-Week Return23.59%-1.68%-0.63%
1-Month Return36.77%-0.67%0.46%
3-Month Return-31.65%-9.11%6.48%
6-Month Return-46.85%-2.8%1.89%
1-Year Return-47.82%-8.53%8.94%
3-Year Return-82.62%8.87%58.67%
5-Year Return-98.6%33.75%91.64%
10-Year Return-98.49%75.55%181.75%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue429.90M507.86M563.24M537.43M515.82M[{"date":"2020-12-31","value":76.33,"profit":true},{"date":"2021-12-31","value":90.17,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.42,"profit":true},{"date":"2024-12-31","value":91.58,"profit":true}]
Cost of Revenue115.98M143.72M183.20M174.21M153.42M[{"date":"2020-12-31","value":63.31,"profit":true},{"date":"2021-12-31","value":78.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.09,"profit":true},{"date":"2024-12-31","value":83.75,"profit":true}]
Gross Profit313.92M364.15M380.04M363.23M362.40M[{"date":"2020-12-31","value":82.6,"profit":true},{"date":"2021-12-31","value":95.82,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.58,"profit":true},{"date":"2024-12-31","value":95.36,"profit":true}]
Gross Margin73.02%71.70%67.47%67.59%70.26%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.19,"profit":true},{"date":"2022-12-31","value":92.4,"profit":true},{"date":"2023-12-31","value":92.56,"profit":true},{"date":"2024-12-31","value":96.21,"profit":true}]
Operating Expenses726.33M1.16B1.36B1.03B719.96M[{"date":"2020-12-31","value":53.39,"profit":true},{"date":"2021-12-31","value":85.36,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":75.9,"profit":true},{"date":"2024-12-31","value":52.92,"profit":true}]
Operating Income(412.40M)(797.06M)(980.41M)(669.32M)(357.56M)[{"date":"2020-12-31","value":-41240500000,"profit":false},{"date":"2021-12-31","value":-79706400000,"profit":false},{"date":"2022-12-31","value":-98040700000,"profit":false},{"date":"2023-12-31","value":-66932100000,"profit":false},{"date":"2024-12-31","value":-35755900000,"profit":false}]
Total Non-Operating Income/Expense10.57M3.19M20.62M33.27M29.03M[{"date":"2020-12-31","value":31.77,"profit":true},{"date":"2021-12-31","value":9.58,"profit":true},{"date":"2022-12-31","value":61.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":87.24,"profit":true}]
Pre-Tax Income(407.24M)(795.80M)(969.25M)(651.30M)(340.74M)[{"date":"2020-12-31","value":-40723500000,"profit":false},{"date":"2021-12-31","value":-79579800000,"profit":false},{"date":"2022-12-31","value":-96924800000,"profit":false},{"date":"2023-12-31","value":-65130100000,"profit":false},{"date":"2024-12-31","value":-34074100000,"profit":false}]
Income Taxes(33.53M)899.00K1.99M2.39M5.88M[{"date":"2020-12-31","value":-569.74,"profit":false},{"date":"2021-12-31","value":15.28,"profit":true},{"date":"2022-12-31","value":33.73,"profit":true},{"date":"2023-12-31","value":40.58,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(373.71M)(796.70M)(971.23M)(653.69M)(346.63M)[{"date":"2020-12-31","value":-37370600000,"profit":false},{"date":"2021-12-31","value":-79669700000,"profit":false},{"date":"2022-12-31","value":-97123300000,"profit":false},{"date":"2023-12-31","value":-65368900000,"profit":false},{"date":"2024-12-31","value":-34662600000,"profit":false}]
Income From Continuous Operations(407.24M)(796.70M)(971.23M)(707.70M)(346.63M)[{"date":"2020-12-31","value":-40723500000,"profit":false},{"date":"2021-12-31","value":-79669700000,"profit":false},{"date":"2022-12-31","value":-97123300000,"profit":false},{"date":"2023-12-31","value":-70770100000,"profit":false},{"date":"2024-12-31","value":-34662600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(373.71M)(796.70M)(971.23M)(653.69M)(346.63M)[{"date":"2020-12-31","value":-37370600000,"profit":false},{"date":"2021-12-31","value":-79669700000,"profit":false},{"date":"2022-12-31","value":-97123300000,"profit":false},{"date":"2023-12-31","value":-65368900000,"profit":false},{"date":"2024-12-31","value":-34662600000,"profit":false}]
EPS (Diluted)(3.11)(7.65)(7.56)(7.87)(4.68)[{"date":"2020-12-31","value":-311,"profit":false},{"date":"2021-12-31","value":-765,"profit":false},{"date":"2022-12-31","value":-756,"profit":false},{"date":"2023-12-31","value":-787,"profit":false},{"date":"2024-12-31","value":-467.97,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BNR
Cash Ratio 1.95
Current Ratio 2.92
Quick Ratio 2.71

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BNR
ROA (LTM) -14.39%
ROE (LTM) -37.03%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BNR
Debt Ratio Lower is generally better. Negative is bad. 0.34
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.66

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BNR
Trailing PE NM
Forward PE NM
P/S (TTM) 0.08
P/B 0.50
Price/FCF 2
EV/R 0.03
EV/Ebitda NM

FAQs

What is Burning Rock Biotech Ltd share price today?

Burning Rock Biotech Ltd (BNR) share price today is $3.7202

Can Indians buy Burning Rock Biotech Ltd shares?

Yes, Indians can buy shares of Burning Rock Biotech Ltd (BNR) on Vested. To buy Burning Rock Biotech Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BNR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Burning Rock Biotech Ltd be purchased?

Yes, you can purchase fractional shares of Burning Rock Biotech Ltd (BNR) via the Vested app. You can start investing in Burning Rock Biotech Ltd (BNR) with a minimum investment of $1.

How to invest in Burning Rock Biotech Ltd shares from India?

You can invest in shares of Burning Rock Biotech Ltd (BNR) via Vested in three simple steps:

  • Click on Sign Up or Invest in BNR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Burning Rock Biotech Ltd shares
What is Burning Rock Biotech Ltd 52-week high and low stock price?

The 52-week high price of Burning Rock Biotech Ltd (BNR) is $7.9. The 52-week low price of Burning Rock Biotech Ltd (BNR) is $2.18.

What is Burning Rock Biotech Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Burning Rock Biotech Ltd (BNR) is 0.50

What is the Market Cap of Burning Rock Biotech Ltd?

The market capitalization of Burning Rock Biotech Ltd (BNR) is $43.39M

What is Burning Rock Biotech Ltd’s stock symbol?

The stock symbol (or ticker) of Burning Rock Biotech Ltd is BNR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top